Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & workings
1.3 Forecast calculations
1.4 Data Sources
1.4.1 Primary
1.4.2 Secondary
1.4.2.1 Paid sources
1.4.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global methotrexate market 3600 synopsis, 2018 – 2032
2.2 Regional trends
2.3 Indication trends
2.4 Mode trends
2.5 Synthesis type trends
Chapter 3 Methotrexate Industry Insights
3.1 COVID- 19 impact analysis
3.2 Industry ecosystem analysis
3.3 Technology landscape
3.4 Regulatory landscape
3.5 Industry impact forces
3.5.1 Growth drivers
3.5.1.1 Rising prevalence of chronic diseases
3.5.1.2 Growing number of drug approvals by regulatory bodies
3.5.1.3 Ongoing research and development using methotrexate drugs
3.5.1.4 Rising technological advancements and demand for personalized medicine
3.5.2 Industry pitfalls & challenges
3.5.2.1 Adverse effects and safety concerns
3.5.2.2 Limited reimbursement and coverage policies
3.6 Growth potential analysis
3.6.1 By indication
3.6.2 By mode
3.6.3 By synthesis type
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.1.1 Novartis AG (Sandoz)
4.1.2 Merck & Co., Inc
4.1.3 Sun Pharmaceutical Industries Ltd
4.2 Competitive positioning matrix, 2022
4.3 Market share/ rank analysis
4.3.1 Global
4.3.2 North America
4.3.3 Europe
4.3.4 Asia Pacific
4.4 Production capacity
4.5 List of top 20 end consumers with contact details/email id
Chapter 5 Methotrexate Market Estimates and Forecast, By Indication (Revenue)
5.1 Key trends, by indication
5.2 Psoriasis
5.3 Rheumatoid arthritis
5.4 Cancer
5.5 Others
Chapter 6 Methotrexate Market Estimates and Forecast, By Mode (Revenue)
6.1 Key trends, by mode
6.2 In-house
6.3 Contract manufacturing
Chapter 7 Methotrexate Market Estimates and Forecast, By Synthesis Type (Revenue)
7.1 Key trends, by synthesis type
7.2 Chemical based API
7.3 Highly potent API (HPAPI)
Chapter 8 Methotrexate Market Estimates and Forecast, By Region (Revenue & Volume)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Russia
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Malaysia
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
Chapter 9 Company Profiles
9.1 Teva Pharmaceutical Industries Ltd
9.2 Sun Pharmaceutical Industries Ltd
9.3 Aurobindo Pharma Ltd
9.4 Lonza Group AG
9.5 Merck & Co., Inc
9.6 Fermion (Orion Corporation)
9.7 Avra Laboratories Pvt Ltd
9.8 Rochem International Inc
9.9 LGM Pharm
9.10 Sandoz AG (Novartis AG
